Skip Navigation

Neuro-Oncology 2009 11(5):529-542; doi:10.1215/15228517-2009-004
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Maes, W.
Right arrow Articles by Van Gool, S. W.
PubMed
Right arrow Articles by Maes, W.
Right arrow Articles by Van Gool, S. W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright 2009 by the Society for Neuro-Oncology

DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma

Wim Maes, Georgina Galicia Rosas, Bert Verbinnen, Louis Boon, Steven De Vleeschouwer, Jan L. Ceuppens and Stefaan W. Van Gool

Clinical Immunology, Department of Experimental Medicine (W.M., G.G.R., B.V., S.D.V., J.L.C., S.W.V.G.), Experimental Neurosurgery and Neuroanatomy (S.D.V.), and Pediatric Hemato-Oncology, Department of Child and Woman (S.W.V.G.), Katholieke Universiteit Leuven, University Hospital Gasthuisberg, Leuven, Belgium; Bioceros BV, Utrecht, The Netherlands (L.B.)

Address correspondence to Stefaan W. Van Gool, University Hospital Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium (Stefaan.VanGool{at}uz.kuleuven.be).


  Abstract

We studied the feasibility, efficacy, and mechanisms of dendritic cell (DC) immunotherapy against murine malignant glioma in the experimental GL261 intracranial (IC) tumor model. When administered prophylactically, mature DCs (DCm) ex vivo loaded with GL261 RNA (DCm-GL261-RNA) protected half of the vaccinated mice against IC glioma, whereas treatment with mock-loaded DCm or DCm loaded with irrelevant antigens did not result in tumor protection. In DCm-GL261-RNA–vaccinated mice, a tumor-specific cellular immune response was observed ex vivo in the spleen and tumordraining lymph node cells. Specificity was also shown in vivo on the level of tumor challenge. Depletion of CD8+ T-cells by anti-CD8 treatment at the time of tumor challenge demonstrated their essential role in vaccine-mediated antitumor immunity. Depletion of CD25+ regulatory T-cells (Tregs) by anti-CD25 (aCD25) treatment strongly enhanced the efficacy of DC vaccination and was itself also protective, independently of DC vaccination. However, DC vaccination was essential to protect the animals from IC tumor rechallenge. No long-term protection was observed in animals that initially received aCD25 treatment only. In mice that received DC and/or aCD25 treatment, we retrieved tumor-specific brain-infiltrating cytotoxic T-lymphocytes. These data clearly demonstrate the effectiveness of DC vaccination for the induction of long-lasting immunological protection against IC glioma. They also show the beneficial effect of Treg depletion in this kind of glioma immunotherapy, even combined with DC vaccination.

Keywords: anti-CD8, anti-CD25, DC immunotherapy, glioma, regulatory T-cells

Received October 23, 2008; Accepted December 24, 2008


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.